Myelofibrosis References

Last updated: 14 March 2025
  1. Alberta Health Services. Clinical care practice guideline: Myelofibrosis. Version 2. Alberta Health Services. http://www.ahs.ca/gur. Feb 2020.
  2. Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. PMID: 29515238
  3. Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018 Feb;8(2):15. doi: 10.1038/s41408-018-0054-y. PMID: 29426921
  4. Harrison CN, McLornan DP. Current treatment algorithm for the management of patients with myelofibro-sis, JAK inhibitors, and beyond. Hematology Am Soc Hematol Educ Program. 2017 Dec;2017(1):489-497. doi: 10.1182/asheducation-2017.1.489. PMID: 29222297
  5. Kröger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015 Nov;29(11):2126-2133. doi: 10.1038/leu.2015.233. PMID: 26293647
  6. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Myeloproliferative neoplasms. Version 1.2021. NCCN. https://www.nccn.org/. 13 Apr 2021.
  7. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): Myeloproliferative neoplasms. Version 1.2020. NCCN. https://www.nccn.org/. 21 May 2020.
  8. National Institute for Health and Care Excellence. Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis. NICE. http://www.nice.org.uk/. 23 Mar 2016.
  9. Reilly JT, McMullin MF, Beer PA, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol. 2012 Aug;158(4):453-471. doi: 10.1111/j.1365-2141.2012.09179.x. PMID: 22651893
  10. Reilly JT, McMullin MF, Beer PA, et al. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for investigation and management of myelofibrosis 2012. Br J Haematol. 2014 Nov;167(3):418-420. doi: 10.1111/bjh.12985. PMID: 24961987
  11. Tefferi A. Clinical manifestations and diagnosis of primary myelofibrosis. UpToDate. https://www.uptodate.com. 13 Aug 2020.
  12. Tefferi A. Management of primary myelofibrosis. UpToDate. https://www.uptodate.com. 18 May 2020.
  13. Tefferi A. Primary Myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2018 Dec;93(12):1551-1560. doi: 10.1002/ajh.25230. PMID: 30039550
  14. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013 Aug;122(8):1395-1398. doi: 10.1182/blood-2013-03-488098. PMID: 23838352
  15. Tefferi A, Guglielmelli P, Pardanani A, et al. Myelofibrosis treatment algorithm 2018. Blood Cancer J. 2018 Aug;8(8):72. doi: 10.1038/s41408-018-0109-0. PMID: 30065290
  16. Vannucchi AM, Barbui T, Cervantes F, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(Suppl 5):v85-v99. doi: 10.1093/annonc/mdv203. PMID: 26242182
  17. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Myeloproliferative neoplasms. Version 2.2022. NCCN. https://www.nccn.org/. Apr 2022.
  18. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): Myeloproliferative neoplasms. Version 2.2024. NCCN. https://www.nccn.org/. 08 Aug 2024.
  19. Tefferi A. Myelofibrosis (MF): Management of primary MF and secondary MF. UpToDate. https://www.uptodate.com. 19 Dec 2023.